Type 1 diabetes(T1D)is a chronic autoimmune condition that destroys insulinproducing beta cells in the pancreas,leading to insulin deficiency and hyperglycemia.The management of T1D primarily focuses on exogenous insu...Type 1 diabetes(T1D)is a chronic autoimmune condition that destroys insulinproducing beta cells in the pancreas,leading to insulin deficiency and hyperglycemia.The management of T1D primarily focuses on exogenous insulin replacement to control blood glucose levels.However,this approach does not address the underlying autoimmune process or prevent the progressive loss of beta cells.Recent research has explored the potential of glucagon-like peptide-1 receptor agonists(GLP-1RAs)as a novel intervention to modify the disease course and delay the onset of T1D.GLP-1RAs are medications initially developed for treating type 2 diabetes.They exert their effects by enhancing glucose-dependent insulin secretion,suppressing glucagon secretion,and slowing gastric emptying.Emerging evidence suggests that GLP-1RAs may also benefit the treatment of newly diagnosed patients with T1D.This article aims to highlight the potential of GLP-1RAs as an intervention to delay the onset of T1D,possibly through their potential immunomodulatory and anti-inflammatory effects and preservation of beta-cells.This article aims to explore the potential of shifting the paradigm of T1D management from reactive insulin replacement to proactive disease modification,which should open new avenues for preventing and treating T1D,improving the quality of life and long-term outcomes for individuals at risk of T1D.展开更多
文摘目的：观察糖化血红蛋白（HbA1c）联合空腹血糖检测在妊娠期糖尿病筛查中的效果。方法选择2013年1月～2013年12月进行产前保健或分娩的孕妇168例，所有孕妇均在行口服75 g葡萄糖耐量试验的同时检测糖化血红蛋白，共发现17例妊娠期糖尿病患者，将其纳入妊娠期糖尿病组，其他151例正常孕妇纳入正常组。对两组进行HbA1c、口服75 g葡萄糖耐量试验。结果妊娠期糖尿病组HbA1c、口服75 g葡萄糖耐量试验1 h PG、2 h PG检测结果均显著高于正常组，且差异存在统计学意义（P＜0.05），而妊娠期糖尿病组空腹血糖与正常组空腹血糖比较，差异无统计学意义（P＞0.05）。两组孕妇HbA1c一次检测成功率均为100%，均显著高于空腹血糖、口服75 g葡萄糖耐量试验一次性检测成功率。结论 HbA1c联合空腹血糖检测在妊娠期糖尿病筛查能够显著提高妊娠期糖尿病的检出率，值得应用于临床。
文摘Type 1 diabetes(T1D)is a chronic autoimmune condition that destroys insulinproducing beta cells in the pancreas,leading to insulin deficiency and hyperglycemia.The management of T1D primarily focuses on exogenous insulin replacement to control blood glucose levels.However,this approach does not address the underlying autoimmune process or prevent the progressive loss of beta cells.Recent research has explored the potential of glucagon-like peptide-1 receptor agonists(GLP-1RAs)as a novel intervention to modify the disease course and delay the onset of T1D.GLP-1RAs are medications initially developed for treating type 2 diabetes.They exert their effects by enhancing glucose-dependent insulin secretion,suppressing glucagon secretion,and slowing gastric emptying.Emerging evidence suggests that GLP-1RAs may also benefit the treatment of newly diagnosed patients with T1D.This article aims to highlight the potential of GLP-1RAs as an intervention to delay the onset of T1D,possibly through their potential immunomodulatory and anti-inflammatory effects and preservation of beta-cells.This article aims to explore the potential of shifting the paradigm of T1D management from reactive insulin replacement to proactive disease modification,which should open new avenues for preventing and treating T1D,improving the quality of life and long-term outcomes for individuals at risk of T1D.
